Company Overview
About Infant Bacterial Therapeutics
Infant Bacterial Therapeutics (IBT) is a Swedish biopharma company developing Lactobacillus reuteri DSM17938 — a probiotic bacterial strain — as a regulated drug (live biotherapeutic product) to prevent necrotizing enterocolitis (NEC) in premature infants. NEC is a devastating gastrointestinal emergency affecting 1–7% of premature newborns, with 30% mortality and severe long-term outcomes in survivors. No approved preventive treatments exist, despite decades of evidence suggesting certain probiotic strains reduce NEC incidence.
Business Model & Competitive Advantage
IBT's approach treats a well-characterized probiotic strain as a pharmaceutical product with rigorous GMP manufacturing, safety testing, and clinical development — a regulatory path enabled by the FDA and EMA's live biotherapeutic framework. The company's Phase 3 PROPREMS-3 trial across 40+ neonatal intensive care units is among the largest neonatal probiotic trials ever conducted, with results expected in 2026.
Competitive Landscape 2025–2026
Founded in 2014 and listed on Nasdaq First North in Stockholm, IBT has partnerships with major neonatal nutrition companies and has raised significant funding to complete the pivotal trial. Regulatory approval would create the first FDA/EMA-approved preventive therapy for NEC, addressing a critical unmet need in neonatal intensive care.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Infant Bacterial Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Adobe Firefly
Adobe Firefly is Adobe's generative AI platform and suite of creative AI tools, launched in March 2023 as Adobe's flagship response to the generative AI revolution. Firefly was purpose-built to be com
80 Acres Farms
80 Acres Farms is a commercial-scale indoor vertical farming company that, following its merger with Soli Organic, operates the largest indoor farming network in North America. The company raised $115
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Compare Infant Bacterial Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Infant Bacterial Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Infant Bacterial Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Infant Bacterial Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →